Palbociclib,Sunitinib,Temsirolimus,Trastuzumab,Pertuzumab,Vemurafenib,Cobimetinib,Regorafenib,Olaparib,Pembrolizumab,Nivolumab,Ipilimumab,Abemaciclib,Talazoparib,Atezolizumab,Entrectinib,Larotrectinib,Tucatinib,Futibatinib
Pfizer,Roche,bayer,Astrazeneca,Merck,bms,eli lilly,Seagen,Otsuka
['breast', 'brca', 'ovarian', 'solid tumor']
tala demonstrated antitumor activity in heavily pretreated pts with advanced solid tumors with brca1/2 mut. additional study is warranted to confirm the efficacy of tala in non-breast, non-ovarian cancer pts with brca1/2 mut. #asco23 #asco2023 
Biomedical Science that Inspires. #medicine #medtwitter #meded #Science #Research #Technology #News